Montréal, Québec, September 22st, 2015 –TVM Capital Life Science yesterday held its 4th annual TVM Capital Autumn Conference which hosted more than 170 participants from around the globe including Asia, MENA, Europe, the United States and Canada, fostering global business networking between senior executives and local life sciences companies looking for financing and partnering opportunities.
Carlos Leitao, Minister of Finance for the Province of Quebec, emphasized, in his keynote speech on the importance of Québec’s life science hub notably its highly skilled labor force, its effective technology innovation system, Quebec’s undeniable know-how and the availability of top-notch financing through specialized venture capital fund.
Dr. Luc Marengere, Managing Partner of TVM Capital Life Science commented: “We appreciate Minister Leitao’s commitment to our conference which we see as a strong endorsement of the relevance of the life sciences and biotech industry to the long term diversification and growth of the Quebec economy.”
TVM Capital Life Science, based in Montreal and Munich, is advising TVM Life Sciences Ventures VII, a venture fund with US$200M in commitments from an international group of investors including Quebec-based Teralys Capital. To date, TVM Life Sciences Ventures VII has made eight investments of which five investments are in the province of Quebec. The latter group of five investments currently account for more than US$50M in overall commitments from a projected goal of a minimum of US$70M to be invested in Quebec-based life sciences companies.
About TVM Capital Life Science
TVM Capital Life Science is providing venture capital to the international pharmaceutical, biopharmaceutical and medical technology industries with more than 30-years of transatlantic investment track record and in excess of US$1.0bn under management. The life science team boasts almost 130 investments and over 90 exits in the last 30 years, including more than 45 initial public offerings on all major U.S. and European stock exchanges, and combines long-standing international investment and company building experience with their track record of dedicated board work, extensive global networks in the world of life science research and product development and a direct knowledge of the local markets. TVM Capital Life Science currently invests from its 7th fund generation, TVM Life Science Ventures VII, with an integrated team of investment professionals. Fund generations III to VI are managed by managing partners, Dr. Helmut M. Schühsler and Dr. Hubert Birner out of the Munich office. The new fund TVM LSV VII is advised by Dr. Hubert Birner and Dr. Luc Marengere out of Munich and Montreal. The fund’s general partner resides in Jersey Channel Island.
About TVM Capital Group
TVM Capital is a group of globally acting venture capital and private equity firms with an operating track record of 30 years. Investment teams have financed more than 250 emerging companies across several industries since 1984. During the last 15 years the firm has become increasingly specialized in the most attractive and high-growth verticals in the broader healthcare markets, with focus areas in financing innovative products and technologies in the European and U.S. biopharmaceutical and medical device markets, as well as healthcare services in the Middle East and India. TVM Capital funds operate globally with dedicated life science venture capital funds advised by group members TVM Life Science Management in Montréal and in Munich, and its healthcare private equity fund managed by TVM Capital Healthcare Partners out of Dubai.
TVM Life Science Ventures VII (GP) Ltd.
11-15 Seaton Place,
St Helier, Jersey
JE4 0QH, Channel Islands
TVM Life Science Management Inc. 2 Place Alexis Nihon, Suite 902 3500 Blvd De Maisonneuve West, Westmount, Montréal, QC H3Z 1X5 Canada
For additional information, please contact:
Dr. Luc Marengere, Managing Partner
email@example.com Phone: 514-931-4111